-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JooBi1YpPaH0N3vlRF3i2ondh68sd4Js4Q+BmQ2rC3w5qs+tctSkM0XpPsvr3Jjb
 6KSJ08ryoFjxUMAM0skeuw==

<SEC-DOCUMENT>0000950123-10-027780.txt : 20100324
<SEC-HEADER>0000950123-10-027780.hdr.sgml : 20100324
<ACCEPTANCE-DATETIME>20100324171526
ACCESSION NUMBER:		0000950123-10-027780
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100319
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100324
DATE AS OF CHANGE:		20100324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELECTRO OPTICAL SCIENCES INC /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		10702470

	BUSINESS ADDRESS:	
		STREET 1:		50 SOUTH BUCKHOUT STREET
		STREET 2:		SUITE 1
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
		BUSINESS PHONE:		914-591-3783

	MAIL ADDRESS:	
		STREET 1:		50 SOUTH BUCKHOUT STREET
		STREET 2:		SUITE 1
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y83510e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): March&nbsp;19, 2010</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Electro-Optical Sciences, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51481</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3986004</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>50 South Buckhout Street, Suite&nbsp;1</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Irvington, New York</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>10533</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code <B>(914)&nbsp;591-3783</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report.)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>















<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">










<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 &#151; Other Events</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On March&nbsp;24, 2010, Electro-Optical Sciences, Inc. issued a press release, a copy of which is
attached as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 &#151; Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits<I>.</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Electro-Optical Sciences, Inc. Press Release, dated March&nbsp;24, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><BR>

Electro-Optical Sciences, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: March 24, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Richard I. Steinhart
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Electro-Optical Sciences, Inc. Press Release, dated March&nbsp;24, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y83510exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MELA Sciences Provides Update on MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> PMA Review</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B><I>Conference call scheduled for 4:30 p.m. EDT</I></B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IRVINGTON, NY, (March&nbsp;24, 2010) &#151; MELA Sciences (NASDAQ: MELA) today announced that it has
received additional questions from U.S. Food and Drug Administration (FDA)&nbsp;regarding the review
status of the Pre-Market Approval (PMA)&nbsp;application of its MelaFind device for early melanoma
detection. The company is actively working to respond to the agency&#146;s questions in the immediate
term. The FDA indicated that the MelaFind PMA review has been extended 180&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;While we are disappointed and surprised to receive a letter from the FDA stating that the PMA is
not approvable at this time, we believe we can address all of the agency&#146;s outstanding questions in
a timely manner and will work diligently to do so,&#148; said Joseph V. Gulfo, MD, President &#038; CEO.
&#147;With a binding protocol agreement in place and expedited review for this breakthrough device, we
had anticipated going before a Panel prior to this type of communication from the agency. We are
also preparing a letter to be sent to the FDA requesting that they convene a Panel to discuss the
application, as appropriate for a product like MelaFind, and as communicated to us by the FDA at
the beginning of, and throughout, the regulatory process.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Given the duration of the review to date, it is helpful to get the questions that the FDA
indicated we need to address in order to put our PMA in an approvable form,&#148; Dr.&nbsp;Gulfo said. &#147;We
remain confident that MelaFind can be a valuable tool to help dermatologists detect melanoma, the
deadliest form of skin cancer, at its earliest, most curable stage. We look forward to working
with the agency to resolve these issues as quickly as possible.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The PMA application is based on the positive results of the company&#146;s landmark pivotal study, which
included 1,831 pigmented skin lesions from 1,383 patients, making this the largest prospective
study ever conducted in melanoma detection. Prior to the start of the study, the company and the
FDA entered into a binding protocol agreement to stipulate the study design, including the
sensitivity and specificity endpoints that should be used to determine the safety and effectiveness
of MelaFind.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We believe our data satisfy the study&#146;s agreed-upon endpoints and we will continue to work with
the agency to move the approval process forward,&#148; Dr.&nbsp;Gulfo said.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;MelaFind is a breakthrough product with the potential to save lives,&#148; Dr.&nbsp;Gulfo said.
&#147;Dermatologists in market research exercises, as well as our expert dermatology consultants, tell
us that MelaFind can provide great help in their effort to detect melanoma, which kills one
American per hour, at the earliest most curable stages. We believe an FDA Panel meeting is
important to our review, and are confident that it would greatly expedite the PMA review process,
and so, we will continue to focus on obtaining a Panel meeting for MelaFind as soon as possible.&#148;
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call Information</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MELA Sciences will host a conference call today at 4:30 PM EDT. To participate in the conference
call, dial (866)&nbsp;831-6234 and use passcode 91967684. International callers may dial (617)&nbsp;213-8854,
using the same passcode. In addition, a live audio of the conference call will be available over
the Internet. Interested parties can access the event through the investor relations section of
<U>www.melasciences.com.</U> For a direct link, click:
<U>http://phx.corporate-ir.net/phoenix.zhtml?c=191863&#038;p=irol-irhome.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If you are unable to participate in the live call, a replay will be available at (888)&nbsp;286-8010,
with passcode 41326247, from 7:30 p.m. EDT on March&nbsp;24, 2010 until April&nbsp;7, 2010. International
callers may access the replay by dialing (617)&nbsp;801-6888, using the same passcode. The webcast will
also be available at <U>www.melasciences.com</U> for the same period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About MELA Sciences</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MELA Sciences is a medical technology company focused on developing MelaFind<SUP style="font-size: 85%; vertical-align: text-top">(R)</SUP>, a
non-invasive and objective computer vision system intended to aid in the early detection of
melanoma. EOS designed MelaFind<SUP style="font-size: 85%; vertical-align: text-top">(R)</SUP> to assist in the evaluation of pigmented skin
lesions, including atypical moles, which have one or more clinical or historical characteristics of
melanoma, before a final decision to biopsy has been rendered. MelaFind<SUP style="font-size: 85%; vertical-align: text-top">(R)</SUP> acquires and
displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and
uses automatic image analysis and statistical pattern recognition to help identify lesions to be
considered for biopsy to rule out melanoma.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">For more information on the company, visit www.melasciences.com.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Safe Harbor

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release includes &#147;forward-looking statements&#148; within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not limited to our plans,
objectives, expectations and intentions and other statements that contain words such as &#147;expects,&#148;
&#147;contemplates,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;believes&#148; and variations of such words or
similar expressions that predict or indicate future events or trends, or that do not relate to
historical matters. These statements are based on our current beliefs or expectations and are
inherently subject to significant uncertainties and changes in circumstances, many of which are
beyond our control. There can be no assurance that our beliefs or expectations will be achieved.
Actual results may differ materially from our beliefs or expectations due to economic, business,
competitive, market and regulatory factors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">For further information contact:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For Investors:<BR>
David Carey<BR>
Lazar Partners, Ltd.<BR>
646-871-8485

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For Media:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Hollister Hovey<BR>
Lazar Partners, Ltd.<BR>
646-871-8485

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
